Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)


Riechelmann R. P. , Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., ...Daha Fazla

CLINICAL COLORECTAL CANCER, cilt.18, sa.3, ss.183-194, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 18 Konu: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clcc.2019.05.003
  • Dergi Adı: CLINICAL COLORECTAL CANCER
  • Sayfa Sayıları: ss.183-194

Özet

This study evaluated safety and quality of life in patients with metastatic colorectal cancer undergoing treatment with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan). Most patients treated with this combination experienced either improvement or stability in quality of life scores. Aflibercept plus FOLFIRI is tolerable in the treatment of patients with metastatic colorectal cancer with a safety profile similar to that seen in previous studies of these individual medications.